Eisai intends to pair Leqembi with other drugs in its pipeline. Still, it is also open to partnering with other companies to advance treatments for the disease.
Tag Archive for: neurodegeneration
The 2023 Alzheimer’s Association International Conference will feature further analyses of the recent traditionally approved Leqembi and a highly anticipated update on Eli Lilly’s donanemab.
After its Biologics License Application was rejected twice by the FDA, BrainStorm’s Phase III data suggest its amyotrophic lateral sclerosis candidate significantly lowers neurofilament light chain levels.
Biomarkers as a surrogate endpoint in ALS will go on trial on March 22 as Biogen and Ionis’s tofersen faces the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee.
AbbVie has ended its collaboration deal with Alector to develop one of two potential Alzheimer’s disease drugs. However, the relationship isn’t totally severed between the pair as they are still working to develop AL002, which is focused on targeting triggering receptors expressed on myeloid cells 2 (TREM2) also for Alzheimer’s Disease.
